{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:08:05Z","timestamp":1770725285826,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated whether or not nitric oxide synthase 3 (NOS3) rs2070744 genotypes can affect the response for lenvatinib treatment in patients with hepatocellular carcinoma (HCC). We evaluated the relation of the NOS3 rs2070744 genotypes to the tumor response, progression-free survival (PFS), and overall survival (OS) as the response for lenvatinib. We also examined the association between fibroblast growth factor receptor (FGFR) gene polymorphisms, a potential feature of lenvatinib, and the response. There were no significant differences between the studies for either PFS or OS, even though patients with the TT genotype had a longer mean PFS (hazard ratio [HR] 0.60; <jats:italic>p<\/jats:italic>\u2009=\u20090.069) and mean OS (HR 0.46; <jats:italic>p<\/jats:italic>\u2009=\u20090.075) than those with the TC\/CC genotypes. However, patients with a single-nucleotide polymorphism (SNP) combination pattern of the NOS3 rs2070744 TC\/CC and FGFR4 rs351855 CT\/TT genotypes had a significantly shorter mean PFS (HR 2.56; <jats:italic>p<\/jats:italic>\u2009=\u20090.006) and mean OS (HR 3.36; <jats:italic>p<\/jats:italic>\u2009=\u20090.013) than those with the other genotypes. The NOS3 rs2070744 genotypes did not influence the clinical response. However, the SNP combination pattern of the NOS3 rs2070744 and FGFR4 rs351855 genotypes may be helpful as treatment effect predictors and prognostic factors for HCC patients treated with lenvatinib.<\/jats:p>","DOI":"10.1038\/s41598-020-73930-3","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T10:05:00Z","timestamp":1602583500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-194X","authenticated-orcid":false,"given":"Shintaro","family":"Azuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Uojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Chuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Numata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Iwabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasaburo","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Atsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"73930_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000492533","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo, M. Extremely high objective response rate of lenvatinib: its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma. Liver Cancer 7, 215\u2013224. https:\/\/doi.org\/10.1159\/000492533 (2018).","journal-title":"Liver Cancer"},{"key":"73930_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000492535","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo, M. Proposal of primary endpoints for TACE combination trials with systemic therapy: lessons learned from 5 negative trials and the positive TACTICS trial. Liver Cancer 7, 225\u2013234. https:\/\/doi.org\/10.1159\/000492535 (2018).","journal-title":"Liver Cancer"},{"key":"73930_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet 391, 1301\u20131314. https:\/\/doi.org\/10.1016\/s0140-6736(18)30010-2 (2018).","journal-title":"Lancet"},{"key":"73930_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000487148","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo, M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. Liver Cancer 7, 1\u201319. https:\/\/doi.org\/10.1159\/000487148 (2018).","journal-title":"Liver Cancer"},{"key":"73930_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u20131173. https:\/\/doi.org\/10.1016\/s0140-6736(18)30207-1 (2018).","journal-title":"Lancet"},{"key":"73930_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.niox.2017.10.009","volume":"72","author":"CH Chen","year":"2018","unstructured":"Chen, C. H. et al. Distinct role of endothelial nitric oxide synthase gene polymorphisms from menopausal status in the patients with sporadic breast cancer in Taiwan. Nitric Oxide 72, 1\u20136. https:\/\/doi.org\/10.1016\/j.niox.2017.10.009 (2018).","journal-title":"Nitric Oxide"},{"key":"73930_CR7","doi-asserted-by":"publisher","first-page":"27988","DOI":"10.18632\/oncotarget.8569","volume":"7","author":"A Casadei Gardini","year":"2016","unstructured":"Casadei Gardini, A. et al. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget 7, 27988\u201327999. https:\/\/doi.org\/10.18632\/oncotarget.8569 (2016).","journal-title":"Oncotarget"},{"key":"73930_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11071023","author":"G Marisi","year":"2019","unstructured":"Marisi, G. et al. ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers11071023 (2019).","journal-title":"Cancers (Basel)"},{"key":"73930_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1684\/ecn.2009.0169","volume":"20","author":"M Ziche","year":"2009","unstructured":"Ziche, M. & Morbidelli, L. Molecular regulation of tumour angiogenesis by nitric oxide. Eur. Cytokine Netw. 20, 164\u2013170. https:\/\/doi.org\/10.1684\/ecn.2009.0169 (2009).","journal-title":"Eur. Cytokine Netw."},{"key":"73930_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1134\/s1022795416020022","volume":"52","author":"SB Diler","year":"2016","unstructured":"Diler, S. B. & \u00d6den, A. The T-786C, G894T, and intron 4 VNTR (4a\/b) polymorphisms of the endothelial nitric oxide synthase gene in prostate cancer cases. Russ. J. Genet. 52, 220\u2013225. https:\/\/doi.org\/10.1134\/s1022795416020022 (2016).","journal-title":"Russ. J. Genet."},{"key":"73930_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.urolonc.2012.01.002","volume":"31","author":"MR Safarinejad","year":"2013","unstructured":"Safarinejad, M. R., Safarinejad, S., Shafiei, N. & Safarinejad, S. Effects of the T-786C, G894T, and Intron 4 VNTR (4a\/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urol. Oncol. 31, 1132\u20131140. https:\/\/doi.org\/10.1016\/j.urolonc.2012.01.002 (2013).","journal-title":"Urol. Oncol."},{"key":"73930_CR12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3897","author":"A Casadei Gardini","year":"2020","unstructured":"Casadei Gardini, A. et al. Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: results of the multicenter prospective INNOVATE study. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3897 (2020).","journal-title":"Clin. Cancer Res."},{"key":"73930_CR13","doi-asserted-by":"publisher","first-page":"12101","DOI":"10.1038\/s41598-019-48045-z","volume":"9","author":"K Ohya","year":"2019","unstructured":"Ohya, K. et al. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. Sci. Rep. 9, 12101. https:\/\/doi.org\/10.1038\/s41598-019-48045-z (2019).","journal-title":"Sci. Rep."},{"key":"73930_CR14","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1007\/s00535-012-0563-6","volume":"47","author":"H Hidaka","year":"2012","unstructured":"Hidaka, H. et al. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. J. Gastroenterol. 47, 1030\u20131035. https:\/\/doi.org\/10.1007\/s00535-012-0563-6 (2012).","journal-title":"J. Gastroenterol."},{"key":"73930_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13531","author":"H Hidaka","year":"2020","unstructured":"Hidaka, H. et al. Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: a prospective cohort study. Hepatol. Res. https:\/\/doi.org\/10.1111\/hepr.13531 (2020).","journal-title":"Hepatol. Res."},{"key":"73930_CR16","doi-asserted-by":"publisher","first-page":"e0122961","DOI":"10.1371\/journal.pone.0122961","volume":"10","author":"MJ Sheu","year":"2015","unstructured":"Sheu, M. J. et al. Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma. PLoS ONE 10, e0122961. https:\/\/doi.org\/10.1371\/journal.pone.0122961 (2015).","journal-title":"PLoS ONE"},{"key":"73930_CR17","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1002\/ijc.23578","volume":"123","author":"Z Ma","year":"2008","unstructured":"Ma, Z. et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int. J. Cancer 123, 2574\u20132579. https:\/\/doi.org\/10.1002\/ijc.23578 (2008).","journal-title":"Int. J. Cancer"},{"key":"73930_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s13402-017-0354-4","volume":"41","author":"L Gao","year":"2018","unstructured":"Gao, L., Shay, C., Lv, F., Wang, X. & Teng, Y. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells: a short report. Cell Oncol. (Dordr) 41, 85\u201391. https:\/\/doi.org\/10.1007\/s13402-017-0354-4 (2018).","journal-title":"Cell Oncol. (Dordr)"},{"key":"73930_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jhep.2008.08.015","volume":"50","author":"HK Ho","year":"2009","unstructured":"Ho, H. K. et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J. Hepatol. 50, 118\u2013127. https:\/\/doi.org\/10.1016\/j.jhep.2008.08.015 (2009).","journal-title":"J. Hepatol."},{"key":"73930_CR20","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","volume":"2","author":"V Guagnano","year":"2012","unstructured":"Guagnano, V. et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2, 1118\u20131133. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0210 (2012).","journal-title":"Cancer Discov."},{"key":"73930_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-016-0478-9","volume":"36","author":"L Gao","year":"2017","unstructured":"Gao, L. et al. FGF19\/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J. Exp. Clin. Cancer Res. 36, 8. https:\/\/doi.org\/10.1186\/s13046-016-0478-9 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"73930_CR22","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/gutjnl-2015-309501","volume":"66","author":"V Tovar","year":"2017","unstructured":"Tovar, V. et al. Tumour initiating cells and IGF\/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut 66, 530\u2013540. https:\/\/doi.org\/10.1136\/gutjnl-2015-309501 (2017).","journal-title":"Gut"},{"key":"73930_CR23","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/aps.2012.206","volume":"34","author":"HM Fang","year":"2013","unstructured":"Fang, H. M., Tian, G., Zhou, L. J., Zhou, H. Y. & Fang, Y. Z. FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer. Acta Pharmacol. Sin. 34, 549\u2013554. https:\/\/doi.org\/10.1038\/aps.2012.206 (2013).","journal-title":"Acta Pharmacol. Sin."},{"key":"73930_CR24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1593\/neo.08450","volume":"10","author":"J Wang","year":"2008","unstructured":"Wang, J., Yu, W., Cai, Y., Ren, C. & Ittmann, M. M. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 10, 847\u2013856. https:\/\/doi.org\/10.1593\/neo.08450 (2008).","journal-title":"Neoplasia"},{"key":"73930_CR25","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1161\/01.cir.99.22.2864","volume":"99","author":"M Nakayama","year":"1999","unstructured":"Nakayama, M. et al. T-786\u2013>C mutation in the 5\u2019-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99, 2864\u20132870. https:\/\/doi.org\/10.1161\/01.cir.99.22.2864 (1999).","journal-title":"Circulation"},{"key":"73930_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.thromres.2004.09.003","volume":"115","author":"S Nagassaki","year":"2005","unstructured":"Nagassaki, S. et al. eNOS genotype is without effect on circulating nitrite\/nitrate level in healthy male population. Thromb. Res. 115, 375\u2013379. https:\/\/doi.org\/10.1016\/j.thromres.2004.09.003 (2005).","journal-title":"Thromb. Res."},{"key":"73930_CR27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1089\/dna.2005.24.218","volume":"24","author":"D Senthil","year":"2005","unstructured":"Senthil, D. et al. Genotype-dependent expression of endothelial nitric oxide synthase (eNOS) and its regulatory proteins in cultured endothelial cells. DNA Cell Biol. 24, 218\u2013224. https:\/\/doi.org\/10.1089\/dna.2005.24.218 (2005).","journal-title":"DNA Cell Biol."},{"key":"73930_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/1756283X15618129","volume":"9","author":"A Granito","year":"2016","unstructured":"Granito, A. et al. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therap. Adv. Gastroenterol. 9, 240\u2013249. https:\/\/doi.org\/10.1177\/1756283X15618129 (2016).","journal-title":"Therap. Adv. Gastroenterol."},{"key":"73930_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/jch.12273","volume":"16","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J. Clin. Hypertens (Greenwich) 16, 177\u2013185. https:\/\/doi.org\/10.1111\/jch.12273 (2014).","journal-title":"J. Clin. Hypertens (Greenwich)"},{"key":"73930_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s1470-2045(08)70003-2","volume":"9","author":"S Wu","year":"2008","unstructured":"Wu, S., Chen, J. J., Kudelka, A., Lu, J. & Zhu, X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 9, 117\u2013123. https:\/\/doi.org\/10.1016\/s1470-2045(08)70003-2 (2008).","journal-title":"Lancet Oncol."},{"key":"73930_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071867","author":"S Shimose","year":"2020","unstructured":"Shimose, S. et al. clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12071867 (2020).","journal-title":"Cancers (Basel)"},{"key":"73930_CR32","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1002\/cam4.2241","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka, A. et al. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions\u2014multicenter analysis. Cancer Med. 8, 3719\u20133728. https:\/\/doi.org\/10.1002\/cam4.2241 (2019).","journal-title":"Cancer Med."},{"key":"73930_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cncr.28972","volume":"121","author":"OP Hamnvik","year":"2015","unstructured":"Hamnvik, O. P. et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 121, 311\u2013319. https:\/\/doi.org\/10.1002\/cncr.28972 (2015).","journal-title":"Cancer"},{"key":"73930_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","volume":"23","author":"SM Bair","year":"2013","unstructured":"Bair, S. M., Choueiri, T. K. & Moslehi, J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc. Med. 23, 104\u2013113. https:\/\/doi.org\/10.1016\/j.tcm.2012.09.008 (2013).","journal-title":"Trends Cardiovasc. Med."},{"key":"73930_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1113\/expphysiol.2007.038588","volume":"93","author":"JA Mitchell","year":"2008","unstructured":"Mitchell, J. A., Ali, F., Bailey, L., Moreno, L. & Harrington, L. S. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp. Physiol. 93, 141\u2013147. https:\/\/doi.org\/10.1113\/expphysiol.2007.038588 (2008).","journal-title":"Exp. Physiol."},{"key":"73930_CR36","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","volume":"56","author":"MH Kappers","year":"2010","unstructured":"Kappers, M. H. et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56, 675\u2013681. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.149690 (2010).","journal-title":"Hypertension"},{"key":"73930_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18030625","author":"OV Ancker","year":"2017","unstructured":"Ancker, O. V., Wehland, M., Bauer, J., Infanger, M. & Grimm, D. The Adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms18030625 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"73930_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address, e. e. e. & European Association for the Study of the, L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 69, 182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019 (2018).","journal-title":"J. Hepatol."},{"key":"73930_CR39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","volume":"31","author":"LT Chen","year":"2020","unstructured":"Chen, L. T. et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann. Oncol. 31, 334\u2013351. https:\/\/doi.org\/10.1016\/j.annonc.2019.12.001 (2020).","journal-title":"Ann. Oncol."},{"key":"73930_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081084","author":"M Kudo","year":"2019","unstructured":"Kudo, M. et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh a liver function: a proof-of-concept study. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers11081084 (2019).","journal-title":"Cancers (Basel)"},{"key":"73930_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000502905","volume":"8","author":"M Kudo","year":"2019","unstructured":"Kudo, M. A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE. Liver Cancer 8, 299\u2013311. https:\/\/doi.org\/10.1159\/000502905 (2019).","journal-title":"Liver Cancer"},{"key":"73930_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000504604","volume":"9","author":"H Uojima","year":"2020","unstructured":"Uojima, H. et al. Skeletal muscle mass influences tolerability and prognosis in hepatocellular carcinoma patients treated with lenvatinib. Liver Cancer 9, 193\u2013206. https:\/\/doi.org\/10.1159\/000504604 (2020).","journal-title":"Liver Cancer"},{"key":"73930_CR43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132 (2010).","journal-title":"Semin. Liver Dis."}],"updated-by":[{"DOI":"10.1038\/s41598-021-86457-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73930-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73930-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73930-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:14:38Z","timestamp":1670361278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73930-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73930"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73930-3","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-021-86457-y","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"9 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-021-86457-y","URL":"https:\/\/doi.org\/10.1038\/s41598-021-86457-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17054"}}